Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
RGS16 Promotes Glioma Progression and Serves as a Prognostic Factor
36 Pages Posted: 11 Jan 2020
More...Abstract
RGS protein family members have recently became new potentially promising therapeutic targets in many cancers. However, as a key member of RGS family, RGS16 has seldom been studied in glioma. The present study was designed to investigate the prognostic value and biological function of RGS16 based on large-scale databases and functional assays in vitro. Here we performed comprehensive analysis for the expression characteristic of RGS16 in Chinese Glioma Genome Atlas (CGGA) microarray database with 301 patients, and validated in The Cancer Genome Atlas (TCGA) microarray and RNA sequencing database. We found that the expression of RGS16 was positively related to the grade of glioma. High-level of RGS16 commonly gathered in glioma of mesenchymal subtype and wild-type IDH1. Moreover, higher expression level of RGS16 was found to be significantly correlated with poor prognosis. The univariate and multivariate Cox regression analysis and ROC curve showed that RGS16 was an independent prognostic factor for glioma patients. Gene ontology analysis, gene set enrichment analysis and gene set variation analysis suggested that the overexpression of RGS16 tightly related to cell proliferation, migration, epithelial-mesenchymal transition (EMT), immune and inflammatory response of glioma. Additionally, RGS16 was involved in immune functions via modulating T-lymphocyte-mediated anti-tumor immunity. Knockdown of RGS16 in glioma cell lines also showed that RGS16 promoted the malignant progress of glioma cell lines. These results suggested that RGS16 closely related to malignant progression of glioma and serves as an independent prognostic factor, especially in GBM patients. Meanwhile, RGS16 was a potential target for immunotherapy of glioma.
Funding Statement: This work was supported by grants from National Natural Science Foundation of China (81972816, 81702460 and 81802994), Beijing Natural Science Foundation (7192057) and Beijing Young Crops Project QML20190506).
Declaration of Interests: No potential conflicts of interest were disclosed.
Ethics Approval Statement: This study was approved by the institutional review board (IRB) of Beijing Tiantan Hospital and informed consent was obtained from all individual participants for CGGA project in this study.
Keywords: regulators of G protein singling 16, glioma, prognosis, cell proliferation, cell migration, immune response
Suggested Citation: Suggested Citation